Is The Time Finally Right For Bispecific Antibodies?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Merck, Lilly, Gilead and Celgene are among the companies striking deals that involve bispecific antibodies. The novel dual-acting drugs have been in development since the 1980s with little success, yet big pharma believes they may finally be coming of age.
You may also be interested in...
Amgen's Cancer Strategy: A Multitude Of Modalities In Immuno-Oncology And Beyond
Amgen is the leader in approved bispecific antibodies and oncolytic viruses, but the company's not shy about expanding its oncology pipeline with even more modes of delivering medicines to cancer patients.
Amgen’s Breakthrough Blincyto Clears FDA At Breakneck Pace, But With REMS Attached
The big biotech’s blinatumomab gains accelerated approval to treat a rare form of ALL. The breakthrough therapy does have a REMS on serious risks and administration concerns.
Amgen Drives Into Immunotherapy With Early Blinatumomab BLA
Bispecific leukemia drug goes to FDA ahead of Phase III data in what could be a signature moment for the agency’s breakthrough designation program – and the company’s cancer deal-making.